Lagos, March 20, 2020 – Authorities in Nigerian megacity Lagos said Friday that hospitals had seen cases of chloroquine poisoning after US President Donald Trump touted the drug as a treatment against the new coronavirus. Trump on Thursday said the anti-malarial drug had been “approved” to treat COVID-19 by America’s Food and Drug Administration, only for the head of the agency to row back and say it had not yet been given a definitive green light. The drug has recently been used to treat coronavirus patients in China and in France, where some researchers said it showed great promise, though scientists agree that only more trials would determine if it really works and is safe.
Health officials in Lagos said there had already been claims online pushing chloroquine as a treatment and that Trump’s message had seen interest surge. “In the last few days, we’ve seen a lot of messages going around on social medias about chloroquine being a cure for coronavirus and in some parts of Lagos, it was no longer available,” Ore Awokoya, senior special assistant to the Lagos state governor on health, told AFP. “But after Donald Trump’s statement it took another dimension, people were massively queueing in front of the pharmacies to buy chloroquine.” She describe the rush to take the drug as “worrying” given that people were “self-medicating without any sort of guidance”. “We’ve already registered two cases of poisoning — the patients have been hospitalised in Lagos — but we will probably see more and more cases in the
coming days,” she said.
Nigeria, Africa’s most populous country, has so far recorded 12 confirmed cases of new coronavirus infections, but testing has been limited. The nation of some 200 million people is seen as highly vulnerable to the global pandemic given its weak health system and high population density. Health authorities in Lagos on Thursday said that there were now cases of “local transmission” of the virus in the city.
By AFP
Sign up to free weekly recap on North Africa and the Sahel
We send out a weekly newsletter every Friday, highlighting the most important events of the week. Sign up today, it is free.
There have been more chatter and speculations about the activities of Russia’s mercenaries, formerly known as the Wagner Group, now reportedly called the Afrika Corps in the Sahel. It is unclear if the name "Afrika Corps" is official, but if so, it certainly confirms...
Free weekly newsletter on events and issues in North Africa and the Sahel
Signup for the most relevant news sent to your email once a week. Please check your email and spam folder for double opt in.
Sahelian juntas push regional integration, abolishing roaming charges and unifying ID documents, but these efforts bolster their control. Amid human rights abuses and worsening jihadist crises, reliance on Russia and regional tensions leave citizens in peril.
French uranium firm Orano faces a standoff with Niger over its Somaïr subsidiary, while Mali has issued arrest warrants for Barrick Gold’s CEO in a contract dispute.
What is happening in Syria today reflects a nation at a crossroads. The decades-long grip of the Assad family has ended, ushering in both relief and a new wave of challenges.
The North Africa Journal is a leading English-language publication focused on North Africa. The Journal covers primarily the Maghreb region and expands its general coverage to the Sahel, Egypt, and beyond, when events in those regions affect the broader North Africa geography. The Journal does not have any affiliation with any institution and has been independent since its founding in 1996. Our position is to always bring our best analysis of events affecting the region, and remain as neutral as humanly possible. Our coverage is not limited to one single topic, but ranges from economic and political affairs, to security, defense, social and environmental issues. We rely on our full staff analysts and editors to bring you best-in-class analysis. We also work with sister company MEA Risk LLC, to leverage the presence on the ground of a solid network of contributors and experts. Information on MEA Risk can be found at www.MEA-Risk.com.